Bausch Health Companies (BHC) Amortization of Deferred Charges (2009 - 2026)
Bausch Health Companies (BHC) reported Amortization of Deferred Charges of $14.0 million for Q1 2026, down 6.67% on a YoY basis from $15.0 million in Q1 2025, and down 36.36% sequentially from $22.0 million in Q4 2025.
Bausch Health Companies (BHC) Amortization of Deferred Charges (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Amortization of Deferred Charges data on file, last reported at $14.0 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 6.67% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $93.0 million (up 66.07% YoY), and the FY2025 full-year result was $94.0 million, up 70.91% from the prior year.
- Amortization of Deferred Charges retreated to $14.0 million in Q1 2026, from $22.0 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $50.0 million in Q2 2022 to a low of $11.0 million in Q1 2023.
- A 5-year average of $19.2 million and a median of $14.0 million in 2022 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges soared 316.67% in 2022 and sank 76.0% in 2023, its largest moves.
- Tracing BHC's Amortization of Deferred Charges over 5 years: stood at $13.0 million in 2022, then climbed by 7.69% to $14.0 million in 2023, then changed by 0.0% to $14.0 million in 2024, then jumped by 57.14% to $22.0 million in 2025, then slumped by 36.36% to $14.0 million in 2026.
- Business Quant data shows BHC's Amortization of Deferred Charges at $14.0 million in Q1 2026, $22.0 million in Q4 2025, and $16.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Bausch Health Companies | 1.68 Bn | 365.34 Mn | 2.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.00 Mn |
| Mar 31, 2026 | 14.00 Mn |
| Dec 31, 2025 | 22.00 Mn |
| Dec 31, 2025 | 22.00 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Sep 30, 2025 | 16.00 Mn |
| Jun 30, 2025 | 41.00 Mn |
| Jun 30, 2025 | 41.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 14.00 Mn |
| Dec 31, 2024 | 14.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | 14.00 Mn |
| Jun 30, 2024 | 14.00 Mn |
| Mar 31, 2024 | 14.00 Mn |
| Mar 31, 2024 | 14.00 Mn |
| Dec 31, 2023 | 14.00 Mn |
| Dec 31, 2023 | 14.00 Mn |